The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
ConclusionCombination treatment of α-PD-1 and α-CTLA-4 is a feasible strategy with enhanced efficacy and acceptable adverse event. Moreover, for some low PD-L1 expression patients, α-CTLA-4 might decrease the risk of resistance to α-PD-1 and demonstrate the synergistic anti-tumor effect.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research